Biogen Inc. (BIIB)
Pre-Market:
| Previous Close | 211.93 |
| Open | 210.32 |
| Bid | 210.81 x 1000 |
| Ask | 215.28 x 1200 |
| Day's Range | 208.13 - 213.68 |
| 52 Week Range | 187.16 - 372.12 |
| Volume | |
| Avg. Volume | 1,108,848 |
| Market Cap | 31.278B |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | 21.86 |
| EPS (TTM) | 9.77 |
| Earnings Date | Jul 20, 2022 - Jul 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 238.74 |
- News Direct
Biogen Celebrates 20 Years of Caring Deeply
Armany is a rising junior at Northeastern University majoring in electrical and computer engineering who developed a passion for science during his time as a Biogen Community Lab student and as a R...
- Business Wire
Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
CAMBRIDGE, Mass. & NEW YORK, June 22, 2022--Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com), the Intelligent Healing Company™, today announced a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS). Through this collaboration, Biogen and Happify Health will help people with MS manage their care journey, improve their wellbeing, learn about treatment options,
- Zacks
Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
